2nd Breast Cancer in Young Women Conference (BCY2)

This text is only available in German.

2nd Breast Cancer in Young Women Conference (BCY2)

4-5 November 2014 - Dublin, Ireland (new dates and location)

Chairs: F. Cardoso, PT - B. Kaufman, IL - O. Pagani, CH - A. Partidge, US

Host Chair: J. Geraghty, IE

Conference Co-ordinator: S. Paluch-Shimon, IL

Early registration: by 31 August 2014

Late registration: by 12 October 2014

On-site registration: after 12 October 2014

We have the pleasure to announce our 2nd Breast Cancer in Young Women Conference, to be held in Dublin, Ireland, from 4 to 5 November 2014. Breast cancer in young women is a devastating and complex disease. Breast cancer in women under 40 strikes when these women are at the peak of their reproductive years, family life and careers and still have many years ahead of them to suffer the long-term effects of treatment or the consequences of recurrent disease. The etiology of breast cancer in this population is poorly understood and most clinical trials focus on women who are over the age of 40, thus little evidence-based data is available about the optimal management of these patients. Further research is much needed in this field. This conference is an opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy and fertility preservation in young women with breast cancer.


- In depth learning of various aspects of breast cancer in young women

- Importance of multi-disciplinary management

- Management of difficult clinical cases


- Hereditary breast cancer

- Diagnostic tools in young women

- Local therapy

- Systemic therapy

- Pregnancy and breast cancer

- Fertility preservation

- Psychosocial aspects

- Management of side effects

- Case discussions


- Medical oncologists

- Surgeons

- Gynaecologists

- Radiation oncologists

- Breast radiologists

- Onco-geneticists

- Pathologists

- Nurses

- Patient advocates


Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Further details are available on our website or on the conference flyer that can be downloaded here.

We hope that you will join us and contribute to further develop the understanding and treatment of this disease. Feel free to contact us with any queries you might have.

Kindest regards,

Francesca Marangoni & Roberta Ventura

Organising Secretariat

European School of Oncology

Via Turati, 29

20121 Milan - Italy

Tel: +39 02 85464525/32

Fax: +39 02 85464545



2. Interdisziplinäre Frauenkonferenz der DGHO

This text is only available in German.

14 November 2014 - Heidelberg, Marriott Hotel
10:00-17:00 Uhr
Anmeldung per Fax an 030 / 27 87 60 89 - 18
oder melden Sie sich hier online unter dem Menüpunkt "Frauenkonferenz 2014" an.



DGHO Service GmbH

Alexanderplatz 1

10178 Berlin

Tel: 030-27 87 60 89 - 37

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it





Alexanderplatz 1

10178 Berlin



German Breast Group - Clinical Reasearch under better Conditions

"Healing through innovation, competence and partnership" has been the vision of the GBG Research Institute since its foundation in April 2003.

These cornerstones of our work allow us professional handling of clinical trials with the highest quality standards, maximum scientific independence and professional neutrality.

Clinical trials exploring new methods of treatment nowadays represent a central element of medical research. In order to achieve a balanced level of knowledge, we consider it to be indispensable that clinical trials are conducted not only by manufacturers of pharmaceutics and medicinal products, but also by academic groups.

Significant to the success of our clinical trials is our collaboration and partnership with investigators and trial staff and their trial participants, as well as the manufacturers of pharmaceutics. We have at our disposal a network of approximately 500 study sites and 1000 clinical investigators. Furthermore, we cooperate with a multitude of both national and international study groups as well as most of the pharmaceutical companies which develop drugs for the treatment of breast cancer.


Trials presented at ASCO 2014

Panel presentations

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – Results from GeparSixto trial



Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP). Loibl et al

GAIN (German Adjuvant Intergroup Node Positive) study: A phase III trial to compare idd-ETC vs. EC-TX in patients with node-positive primary breast cancer – final efficacy analysis. Möbus et al

Prognostic score for Luminal A-like breast cancer patients: the STage-Age-Receptors (STAR) score. Fontanella et al



more news

more News...